Monotherapy (first choice drug) for treatment: partial seizures with or without secondary generalization in adults and adolescents over 16 years of age who were first diagnosed with epilepsy. As an additional therapy for treatment: partial seizures with or without secondary generalization in adults and children with a body weight of 7 kg, patients with epilepsy (in this dosage form); myoclonic seizures in adults and adolescents over 12 years of age with juvenile myoclonic epilepsy; primary generalization of convulsive (tonic-clonic) seizures in adults and adolescents older than 12 years, patients with idiopathic generalized epilepsy.
Active substance: levetiracetam;
1 tablet contains levetiracetam 250 mg or 500 mg;
excipients: microcrystalline cellulose, copovidone, crospovidone, pregelatinized corn starch, magnesium stearate, coating for coating Opadry II White (polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide (E171)).
Levicitam Release form
Package. 10 tablets in a blister; 3 or 6 blisters in a cardboard box.
Levicitam Dosage form
Basic physical and chemical properties: tablets 250 mg or 500 mg: tablets of a round shape, with a biconvex surface, film-coated white.
Levetiracetam is a pyrrolidone derivative (S-enantiomer of alpha-ethyl-2-oxo-1-pyrrolidine-acetamide), which differs in chemical structure from known antiepileptic drugs. The mechanism of action of levetiracetam is not well understood, but it has been established that it differs from the mechanism of action of known antiepileptic drugs. Based on in vitro and in vivo studies, it is assumed that levetiracetam does not alter the basic characteristics of the nerve cell and normal neurotransmission. In vitro studies have shown that levetiracetam affects the internal neuronal level of Ca2 + by partially suppressing the current through the N-type Ca2 + channels and reducing the release of Ca2 + from intraneuronal stores. It also partially neutralizes the inhibition of GABA – and glycine-regulated current caused by the action of zinc and β-carbolines. In addition, in in vitro studies, levetiracetam binds to specific sites in rodent brain tissues. The binding site is the synaptic vesicle protein 2A, which is involved in vesicle fusion and neurotransmitter release. The relationship of levetiracetam and the corresponding analogs to the synaptic vesicle protein 2A correlated with the potency of their anticonvulsant action in models of audiogenic epilepsy in mice. These results suggest that the interaction between levetiracetam and synaptic vesicle protein 2A may partially explain the mechanism of antiepileptic action of the drug.
Levetiracetam provides protection against seizures in a wide range of animal models of partial and primary seizure seizures, without causing a prodominal effect. The main metabolite is inactive.
The activity of the drug has been confirmed in relation to both focal and generalized epileptic seizures (epileptiform manifestations / photoparoxysmal reaction).